SEC Form 4 · accession 0001213900-17-006882
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lynda Sarah Cranston
Director
Period of report
Jun 26, 2017
Accepted (ET)
Jun 28, 2017 · 11:31 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 26, 2017 | P | 2,083 | $3.60 | A | 2,344 | I | Note |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $10,000. Reported price is based on exchange rate of 0.75.
- F2Shares are held by J.G. Cranston & Associates, Inc.